The year 2021 marks the centennial of Banting and Best’s landmark description of the discovery of insulin. This discovery and insulin’s rapid clinical deployment effectively transformed type 1 diabetes from a fatal diagnosis into a medically manageable chronic condition. In this Review, we describe key accomplishments leading to and building on this momentous occasion in medical history, including advancements in our understanding of the role of insulin in diabetes pathophysiology, the molecular characterization of insulin and the clinical use of insulin. Achievements are also viewed through the lens of patients impacted by insulin therapy and the evolution of insulin pharmacokinetics and delivery over the past 100 years. Finally, we reflect on the future of insulin therapy and diabetes treatment, as well as challenges to be addressed moving forward, so that the full potential of this transformative discovery may be realized.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Nature Nanotechnology Open Access 09 October 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review
Communications Medicine Open Access 05 October 2023
Robustness of a multivariate composite score when evaluating distress of animal models for gastrointestinal diseases
Scientific Reports Open Access 14 February 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Bliss, M. The Discovery of Insulin (Univ. Chicago Press, 1982).
Nerup, J. et al. Cell-mediated immunity in diabetes mellitus. Proc. R. Soc. Med. 67, 506–513 (1974).
Gale, E. A. The discovery of type 1 diabetes. Diabetes 50, 217–226 (2001).
Bliss, M. The history of insulin. Diabetes Care 16, 4–7 (1993).
Bottazzo, G., Florin-Christensen, A. & Doniach, D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 304, 1279–1283 (1974).
Singal, D. P. & Blajchman, M. A. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes 22, 429–432 (1973).
Nerup, J. et al. HL-A antigens and diabetes mellitus. Lancet 2, 864–866 (1974).
Cudworth, A. G. & Woodrow, J. C. HL-A antigens and diabetes mellitus. Lancet 2, 1153 (1974).
Gemmill, C. L. The Greek concept of diabetes. Bull. N. Y. Acad. Med. 48, 1033–1036 (1972).
Allan, F. N. The writings of Thomas Willis, M.D.; diabetes three hundred years ago. Diabetes 2, 74–77 (1953).
Dobson, M. Nature of the urine in diabetes. Med. Obs. Inq. 5, 298–310 (1776).
v. Mering, J. & Minkowski, O. Diabetes mellitus nach Pankreasexstirpation. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 26, 371–387 (1890).
Sakula, A. Paul Langerhans (1847–1888): a centenary tribute. J. R. Soc. Med. 81, 414–415 (1988).
Laguesse, G. E. Sur la formation des îlots de Langerhans dans le pancréas. C. R. Seances Soc. Biol. Fil. 5, 819–820 (1893).
Goet, J. P. Gustave Edouard Laguesse; his demonstration of the significance of the Islands of Langerhans. Diabetes 2, 322–324 (1953).
De Meyer, J. Action de la sécrétion interne du pancréas sur différents organes et en particulier sur la sécrétion rénale. Arch. Fisiol. 7, 96–99 (1909).
Lindsten, J. August Krogh and the Nobel Prize to Banting and Macleod. The Nobel Prize https://www.nobelprize.org/prizes/themes/august-krogh-and-the-nobel-prize-to-banting-and-macleod/ (2 April 2001).
Banting, F. G., Best, C. H., Collip, J. B., Campbell, W. R. & Fletcher, A. A. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12, 141 (1922).
Lancereaux, E. Le diabète maigre, ses symptômes, son évolution, son pronostic et son traitement. Union Med. 29, 161 (1880).
Pincus, G., Joslin, E. & White, P. The age-incidence relations in diabetes mellitus. Am. J. Med. Sci. 188, 116–121 (1934).
MacLean, H. Some observations on diabetes and insulin in general practice. Postgrad. Med. J. 1, 73–77 (1926).
Falta, W. & Boller, R. Insulärer und insulinresistenter Diabetes. Klin. Wochenschr. 10, 438–443 (1931).
Himsworth, H. P. Diabetes mellitus: its differentiation into insulin-sensitive and insulin insensitive types. Lancet 227, 127–130 (1936).
Bornstein, J. & Lawrence, R. Two types of diabetes mellitus, with and without available plasma insulin. Br. Med. J. 1, 732 (1951).
Wrenshall, G. A., Bogoch, A. & Ritchie, R. Extractable insulin of pancreas: correlation with pathological and clinical findings in diabetic and nondiabetic cases. Diabetes 1, 87–107 (1952).
Yalow, R. S. & Berson, S. A. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 39, 1157–1175 (1960).
Himsworth, H. P. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Int. J. Epidemiol. 42, 1594–1598 (2013).
Wild, S. H. & Byrne, C. D. Commentary: sub-types of diabetes–what’s new and what’s not. Int. J. Epidemiol. 42, 1600–1602 (2013).
Anderson, J., Goudie, R., Gray, K. & Timbury, G. Auto-antibodies in Addison’s disease. Lancet 269, 1123–1124 (1957).
Roitt, I., Doniach, D., Campbell, P. & Hudson, R. V. Auto-antibodies in Hashimoto’s disease (lymphadenoid goitre). Lancet 268, 820–821 (1956).
Witebsky, E., Rose, N. R., Terplan, K., Paine, J. R. & Egan, R. W. Chronic thyroiditis and autoimmunization. J. Am. Med. Assoc. 164, 1439–1447 (1957).
Irvine, W., Clarke, B., Scarth, L., Cullen, D. & Duncan, L. Thyroid and gastric autoimmunity in patients with diabetes mellitus. Lancet 296, 163–168 (1970).
Ungar, B., Stocks, A., Martin, F., Whittingham, S. & Mackay, I. Intrinsic-factor antibody in diabetes mellitus. Lancet 290, 77–78 (1967).
Renold, A. E., Soeldner, S. & Steinke, J. in Ciba Foundation Symposium ‐ Aetiology of Diabetes Mellitus and its Complications (Colloquia on Endocrinology) Vol. 15 (eds. M.P. Cameron, M. P. & O’Connor, M.) 122–139 (Wiley, 1964).
Lacy, P. E. & Wright, P. H. Allergic interstitial pancreatitis in rats injected with guinea pig anti-insulin serum. Diabetes 14, 634–642 (1965).
Heydinger, D. K. & Lacy, P. E. Islet cell changes in the rat following injection of homogenized islets. Diabetes 23, 579–582 (1974).
Lecompte, P. M. Insulitis in early juvenile diabetes. AMA Arch. Pathol. 66, 450–457 (1958).
Gepts, W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14, 619–633 (1965).
DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214–E223 (1979).
Reaven, G. M. Insulin resistance in noninsulin-dependent diabetes mellitus. Does it exist and can it be measured?. Am. J. Med. 74, 3–17 (1983).
Shen, S. W., Reaven, G. M. & Farquhar, J. W. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J. Clin. Invest. 49, 2151–2160 (1970).
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28, 1039–1057 (1979).
Makino, S., Muraoka, Y., Kishimoto, Y. & Hayashi, Y. Genetic analysis for insulitis in NOD mice. Jikken Dobutsu 34, 425–431 (1985).
Nakhooda, A. F., Like, A. A., Chappel, C. I., Wei, C. N. & Marliss, E. B. The spontaneously diabetic Wistar rat (the “BB” rat). Studies prior to and during development of the overt syndrome. Diabetologia 14, 199–207 (1978).
Eisenbarth, G. S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314, 1360–1368 (1986).
Gottlieb, M. S. & Root, H. F. Diabetes mellitus in twins. Diabetes 17, 693–704 (1968).
Tattersall, R. B. & Pyke, D. A. Diabetes in identical twins. Lancet 2, 1120–1125 (1972).
Thorsby, E. A short history of HLA. Tissue Antigens 74, 101–116 (2009).
Davies, J. L. et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371, 130–136 (1994).
Bennett, S. T. et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat. Genet. 9, 284–292 (1995).
Vafiadis, P. et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 15, 289–292 (1997).
Pugliese, A. et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet. 15, 293–297 (1997).
Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics. Nucleic Acids Res. 47, D1005–D1012 (2019).
Coomans de Brachène, A. et al. IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia 61, 636–640 (2018).
Marroqui, L. et al. Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia 60, 656–667 (2017).
Fløyel, T. et al. CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients. Proc. Natl Acad. Sci. USA 111, 10305–10310 (2014).
Eizirik, D. L. et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 8, e1002552 (2012).
Eizirik, D. L., Colli, M. L. & Ortis, F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5, 219–226 (2009).
Lee, H. et al. Beta cell dedifferentiation induced by IRE1α deletion prevents type 1 diabetes. Cell Metab. 31, 822–836 (2020).
Bottazzo, G. F. Lawrence lecture. Death of a beta cell: homicide or suicide? Diabet. Med. 3, 119–130 (1986).
Battaglia, M. et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care 43, 5–12 (2020).
Krischer, J. P. et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58, 980–987 (2015).
Ziegler, A. G. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. J. Am. Med. Assoc. 309, 2473–2479 (2013).
Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964–1974 (2015).
Feutren, G. et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2, 119–124 (1986).
Stiller, C. R. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223, 1362–1367 (1984).
Kahn, S. E. et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42, 1663–1672 (1993).
Bergman, R. N., Phillips, L. S. & Cobelli, C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J. Clin. Invest. 68, 1456–1467 (1981).
Evans-Molina, C., Hatanaka, M. & Mirmira, R. G. Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus. Diabetes Obes. Metab. 15, 159–169 (2013).
Butler, A. E. et al. β-cell deficit in obese type 2 diabetes, a minor role of β-cell dedifferentiation and degranulation. J. Clin. Endocrinol. Metab. 101, 523–532 (2016).
Guo, S. et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J. Clin. Invest. 123, 3305–3316 (2013).
Lillioja, S. et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N. Engl. J. Med. 318, 1217–1225 (1988).
Martin, B. C. et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340, 925–929 (1992).
Saad, M. F. et al. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1, 1356–1359 (1989).
Tabak, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009).
Trico, D., Natali, A., Arslanian, S., Mari, A. & Ferrannini, E. Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. JCI Insight 3, e124912 (2018).
Duggirala, R. et al. Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am. J. Hum. Genet 64, 1127–1140 (1999).
Grant, S. F. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38, 320–323 (2006).
Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat. Genet. 50, 1505–1513 (2018).
McCarthy, M. I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 363, 2339–2350 (2010).
Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).
Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018).
Dennis, J. M., Shields, B. M., Henley, W. E., Jones, A. G. & Hattersley, A. T. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 7, 442–451 (2019).
Crowfoot, D. X-ray single crystal photographs of insulin. Nature 135, 591–592 (1935).
Adams, M. J. et al. Structure of rhombohedral 2 zinc insulin crystals. Nature 224, 491–495 (1969).
Howard, J. A. Dorothy Hodgkin and her contributions to biochemistry. Nat. Rev. Mol. Cell Biol. 4, 891–896 (2003).
Sanger, F. & Tuppy, H. The amino-acid sequence in the phenylalanyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem. J. 49, 463–481 (1951).
Sanger, F. & Tuppy, H. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem. J. 49, 481–490 (1951).
Sanger, F. & Thompson, E. The amino-acid sequence in the glycyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem. J. 53, 353–366 (1953).
Sanger, F. & Thompson, E. The amino-acid sequence in the glycyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem. J. 53, 366–374 (1953).
Berg, P. Fred Sanger: a memorial tribute. Proc. Natl Acad. Sci. USA 111, 883–884 (2014).
Ryle, A. P., Sanger, F., Smith, L. F. & Kitai, R. The disulphide bonds of insulin. Biochem. J. 60, 541–556 (1955).
Sanger, F. Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes. Science 129, 1340–1344 (1959).
Steiner, D. F. Adventures with insulin in the islets of Langerhans. J. Biol. Chem. 286, 17399–17421 (2011).
Steiner, D. F. & Oyer, P. E. The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proc. Natl Acad. Sci. USA 57, 473–480 (1967).
Chance, R. E., Ellis, R. M. & Bromer, W. W. Porcine proinsulin: characterization and amino acid sequence. Science 161, 165–167 (1968).
De Meyts, P. Insulin and its receptor: structure, function and evolution. Bioessays 26, 1351–1362 (2004).
Shoelson, S. et al. Three mutant insulins in man. Nature 302, 540–543 (1983).
Garin, I. et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc. Natl Acad. Sci. USA 107, 3105–3110 (2010).
Stoy, J. et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl Acad. Sci. USA 104, 15040–15044 (2007).
Liu, M. et al. Impaired cleavage of preproinsulin signal peptide linked to autosomal-dominant diabetes. Diabetes 61, 828–837 (2012).
Rege, N. K. et al. Evolution of insulin at the edge of foldability and its medical implications. Proc. Natl Acad. Sci. USA 117, 29618–29628 (2020).
Sims, E. K. et al. Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care 39, 1519–1526 (2016).
Loopstra-Masters, R. C., Haffner, S. M., Lorenzo, C., Wagenknecht, L. E. & Hanley, A. J. Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia 54, 3047–3054 (2011).
Ovalle, F. et al. Understanding concentrated insulins: a systematic review of randomized controlled trials. Curr. Med. Res. Opin. 34, 1029–1043 (2018).
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J. & Wright, E. E. The evolution of insulin and how it informs therapy and treatment choices. Endocr. Rev. 41, 733–755 (2020).
Murray, I. & Wilson, R. B. The new insulins—lente, ultralente, and semilente. Br. Med. J. 2, 1023–1026 (1953).
Fraser, L. Cloning insulin. Genentech https://www.gene.com/stories/cloning-insulin (7 April 2016).
Lavaux, J. P., Ooms, H. A. & Christiansen, A. H. Insulin antibodies in insulin-treated patients; a clinical trial with highly purified insulins. Int. Congr. Ser. 316, 40–46 (1973).
Institute of Medicine. Sources of Medical Technology: Universities and Industry (National Academies Press, 1995).
Goeddel, D. V. et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76, 106–110 (1979).
The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).
United Kingdom Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
United Kingdom Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br. Med. J. 310, 83–88 (1995).
Biester, T., Kordonouri, O. & Danne, T. Pharmacological properties of faster-acting insulin aspart. Curr. Diabetes Rep. 17, 101 (2017).
Pieber, T. R., Eugene-Jolchine, I. & Derobert, E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 23, 157–162 (2000).
US Food and Drug Administration. Levemir insulin detemir[rDNA origin] injection drug approval package. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_LevemirTOC.cfm (2005).
Kurtzhals, P. et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 54, S426 (2011).
Kesavadev, J., Saboo, B., Krishna, M. B. & Krishnan, G. Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther. 11, 1251–1269 (2020).
Oleck, J., Kassam, S. & Goldman, J. D. Commentary: why was inhaled insulin a failure in the market? Diabetes Spectr. 29, 180–184 (2016).
Kovatchev, B. A century of diabetes technology: signals, models, and artificial pancreas control. Trends Endocrinol. Metab. 30, 432–444 (2019).
Kadish, A. H. Automation control of blood sugar. I. A servomechanism for glucose monitoring and control. Am. J. Med. Electron. 3, 82–86 (1964).
Albisser, A. M. et al. An artificial endocrine pancreas. Diabetes 23, 389–396 (1974).
Kesavadev, J., Srinivasan, S., Saboo, B., Krishna, B. M. & Krishnan, G. The do-it-yourself artificial pancreas: a comprehensive review. Diabetes Ther. 11, 1217–1235 (2020).
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002).
Sims, E. K. et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci. Transl. Med. 13, eabc8980 (2021).
Ferrat, L. A. et al. A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nat. Med. 26, 1247–1255 (2020).
Ziegler, A. G. et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. J. Am. Med. Assoc. 323, 339–351 (2020).
Deacon, C. F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 16, 642–653 (2020).
Rieg, T. & Vallon, V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61, 2079–2086 (2018).
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
Russell, S. J. et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N. Engl. J. Med. 371, 313–325 (2014).
Haidar, A. et al. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 3, 17–26 (2015).
D’Amour, K. A. et al. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat. Biotechnol. 23, 1534–1541 (2005).
Hogrebe, N. J., Augsornworawat, P., Maxwell, K. G., Velazco-Cruz, L. & Millman, J. R. Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat. Biotechnol. 38, 460–470 (2020).
Rezania, A. et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32, 1121–1133 (2014).
Evans-Molina, C., Vestermark, G. L. & Mirmira, R. G. Development of insulin-producing cells from primitive biologic precursors. Curr. Opin. Organ Transplant. 14, 56–63 (2009).
Agulnick, A. D. et al. Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo. Stem Cells Transl. Med. 4, 1214–1222 (2015).
Nair, G. G. et al. Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived β cells. Nat. Cell Biol. 21, 263–274 (2019).
Simeone, J. C. et al. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States. J. Manag. Care Spec. Pharm. 26, 1399–1410 (2020).
Beran, D., Lazo-Porras, M., Mba, C. M. & Mbanya, J. C. A global perspective on the issue of access to insulin. Diabetologia 64, 954–962 (2021).
Cefalu, W. T. et al. Insulin Access and Affordability Working Group: conclusions and recommendations. Diabetes Care 41, 1299–1311 (2018).
Sharpey-Schäfer, E. A. An Introduction to the Study of the Endocrine Glands and Internal Secretions: Lane Medical Lectures, 1913 (Stanford Univ. Press, 1914).
Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
Goldfine, A. B. et al. Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. Proc. Natl Acad. Sci. USA 100, 2724–2729 (2003).
Utzschneider, K. M. et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335–341 (2009).
Diabetes Prevention Trial–Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685–1691 (2002).
Morgan, N. G. & Richardson, S. J. Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made. Diabetologia 61, 2499–2506 (2018).
Campbell-Thompson, M. et al. Network for pancreatic organ donors with diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab. Res. Rev. 28, 608–617 (2012).
Al-Tabakha, M. M. Future prospect of insulin inhalation for diabetic patients: the case of Afrezza versus Exubera. J. Control. Release 215, 25–38 (2015).
Katzung, B. G. M., Susan B. & Trevor, A. J. Basic & Clinical Pharmacology 12th edn (McGraw Hill, 2012).
Tibaldi, J. M. Evolution of insulin: from human to analog. Am. J. Med. 127, S25–S38 (2014).
Polonsky, K. S. The past 200 years in diabetes. N. Engl. J. Med. 367, 1332–1340 (2012).
Gill, G., Jones, K., Smyth, C., Bain, S. & Barnett, A. Memories of the early years of insulin treatment in the UK. Pract. Diabetes Int. 20, 103–107.
Padmore, E. Reflections on six decades of living with insulin-treated diabetes. J. Diabetes Nurs. 10, 366–370 (2009).
Clothier, C. Living with diabetes in the 1950s. J. Diabetes Nurs. 23, 1–8 (2019).
Research in the laboratory of C.E.-M. is supported by the NIH grants R01 DK093954, R21 DK119800, U01DK127786, R01DK127308 and P30DK097512; the VA Merit Award I01BX001733; and the JDRF grant 2-SRA-2019-834-S-B; as well as gifts from the Sigma Beta Sorority, the Ball Brothers Foundation, and the George and Frances Ball Foundation. E.K.S. is supported by R03 DK117253, R01DK121929 and JDRF 2-SRA-2017-498-M-B. L.A.D. is supported by 1UL1TR002529. We thank the following individuals who willingly shared their personal experiences of living with type 1 diabetes: James C. Garmey (diagnosed 1965); Lis Warren (diagnosed 1965); Karen Stancombe (diagnosed 1967); Debra A. Ignaut (diagnosed 1977); Patrick A. Fueger (diagnosed 1984); Todd Nebesio (diagnosed 1988); Roger Felton (diagnosed 1990); Jason Spaeth (diagnosed 1995) and his wife, Aubrey Spaeth; Kate Haynes (diagnosed 2002); and Staci Weaver (diagnosed 2006).
The authors declare no competing interests.
Peer review information Nature Medicine thanks the anonymous reviewers for their contribution to the peer review of this work. Joao Monteiro and Karen O’Leary were the primary editors on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sims, E.K., Carr, A.L.J., Oram, R.A. et al. 100 years of insulin: celebrating the past, present and future of diabetes therapy. Nat Med 27, 1154–1164 (2021). https://doi.org/10.1038/s41591-021-01418-2
This article is cited by
Nature Nanotechnology (2023)
Nature Reviews Endocrinology (2023)
Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences
Nature Biomedical Engineering (2023)
Robustness of a multivariate composite score when evaluating distress of animal models for gastrointestinal diseases
Scientific Reports (2023)
Nature Catalysis (2023)